Complement inhibitor therapy for geographic atrophy — the C3 inhibitor pegcetacoplan (Syfovre) and C5 inhibitor avacincaptad pegol (Izervay) representing the first approved GA treatments and the foundation of the emerging GA pharmaceutical market — creates the commercial opportunity, with the China Geographic Atrophy Market reflecting complement inhibition as the foundational therapeutic commercial market.

Complement pathway's role in GA — the complement system dysregulation (genetic associations with CFH, C3, C9, CFB genes establishing complement's central pathogenic role) creating the mechanistic rationale for complement inhibitor therapy. The CFH Y402H genetic variant's strong association with AMD and GA establishing the complement-AMD connection that guided complement inhibitor development.

Syfovre (pegcetacoplan) mechanism and efficacy — the monthly or every-other-month intravitreal injection inhibiting C3 complement protein upstream in the complement cascade — representing the more proximal complement inhibition approach. The OAKS trial's twelve-month data showing eighteen percent (monthly) to fourteen percent (every other month) lesion growth reduction versus sham and the GALE twenty-four-month extension showing sustained efficacy.

Avacincaptad pegol (Izervay) differentiation — the C5 complement inhibitor working downstream in the complement cascade preventing C5a and C5b formation — creating the alternative mechanism complement inhibitor. The GATHER1 and GATHER2 trial thirty-five percent lesion growth reduction at twelve months creating the competitive efficacy data.

Do you think NMPA approval of complement inhibitors for GA will follow within two to three years of US FDA approval, and what timeline is realistic for Chinese patients to access these treatments?

FAQ

What is pegcetacoplan (Syfovre) and what does clinical evidence show? Syfovre (pegcetacoplan, Apellis): C3 complement inhibitor; mechanism: pegylated compstatin analog binding C3 and C3b preventing complement cascade amplification; route: intravitreal injection; dosing: monthly or every other month; evidence: OAKS trial (one thousand-plus patients): monthly arm thirty-six percent lesion growth reduction vs sham at twelve months; EOMonthly twenty-two percent; DERBY trial: similar results; GALE extension: twenty-four month data showing sustained lesion growth reduction; sustained safety profile; adverse events: intraocular inflammation (approximately eight percent any grade, approximately one percent severe), injection site reactions; commercial positioning: monthly dosing more effective; most patients dosed monthly or every other month.

What is avacincaptad pegol (Izervay)? Izervay (avacincaptad pegol, IVERIC Bio/Astellas): RNA aptamer-based C5 complement inhibitor; mechanism: inhibits C5 cleavage preventing C5a (inflammatory) and C5b (MAC formation) generation; dosing: monthly intravitreal injection; evidence: GATHER1 (randomized, double-masked, sham-controlled): thirty-five percent lesion growth reduction at twelve months versus sham (Gathering 2 MG dose); GATHER2: confirmed efficacy; FDA approved August 2023; adverse events: intraocular inflammation (lower than pegcetacoplan), vasculitis concern requiring monitoring; commercial situation: IVERIC Bio acquired by Astellas; Astellas commercializing in US; NMPA application in planning; monthly injection only (no every-other-month option currently); competitive differentiation: potentially lower inflammation rate.

#ChinaGeographicAtrophy #Syfovre #Pegcetacoplan #ComplementGA #IzervayGA #GAtreatment